Health
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide – Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of…
Height Gain is Maintained in 2nd Year of Treatment
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society’s Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children’s Research Institute, Royal Children’s Hospital, University…
-
General23 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
General13 hours agoMan dies in daylight shooting in Sydney’s north-west
-
Noosa News22 hours agoCouncil steps up staff protection after surge in abuse
-
Business15 hours agoOrd Minnett names 2 ASX 200 shares to buy